亚太遗传性癌症检测市场，按测试类型（多面板集和单点基因测试）、诊断类型（活检、成像、实验室测试）、技术（测序、聚合酶链反应 (PCR)、微阵列）、疾病类型（遗传性乳腺癌和卵巢癌综合征、考登综合征、林奇综合征、遗传性白血病和血液系统恶性肿瘤综合征、家族性腺瘤性息肉病 (FAP)、李-法美尼综合征、希佩尔-林道病、多发性内分泌肿瘤 (MEN) 综合征）、最终用户（医院、诊所、实验室、放射中心、诊断中心、其他）、分销渠道（直接招标、零售销售）、趋势和预测到 2029 年。
亚太地区遗传性癌症检测市场分析与洞察
癌症是一种遗传性疾病，由控制细胞功能的基因发生某些突变引起，尤其影响细胞的生长和繁殖。遗传基因突变是造成大约 5-10% 的癌症的原因。研究人员已将特定基因的突变与 50 多种遗传性癌症综合征联系起来，这些综合征通过某些癌症的发展影响人们。此外，约 5-10% 的乳腺癌病例与从父母那里遗传的基因突变有关。BRCA1 和 BRCA2 基因的差异占主导地位。BRCA1 突变的女性一生患乳腺癌的风险约为 72%，而 BRCA2 突变的女性患乳腺癌的风险约为 69%。因此，癌症患病率的上升推动了遗传性癌症的稳步增长，从而推动了遗传性癌症检测市场的增长。此外，对非侵入性检测方法的需求增加以及对更高质量医疗保健和早期诊断的需求不断增长是市场增长的主要机会。此外，遗传性癌症检测面临的道德挑战和市场参与者之间日益激烈的竞争是市场增长面临的关键挑战。
然而，严格的癌症诊断规定和与测试相关的高昂成本可能会阻碍市场的增长。
Data Bridge Market Research 分析，亚太地区遗传性癌症检测市场预计到 2029 年将达到 21.6905 亿美元，预测期内复合年增长率为 14.0%。本市场报告还深入介绍了定价分析、专利分析和技术进步。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制至 2019 - 2015） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按测试类型（多组和单点基因测试）、诊断类型（活检、成像、实验室测试）、技术（测序、聚合酶链反应 (PCR)、微阵列）、疾病类型（遗传性乳腺癌和卵巢癌综合征、考登综合征、林奇综合征、遗传性白血病和血液系统恶性肿瘤综合征、家族性腺瘤性息肉病 (FAP)、李-法美尼综合征、希佩尔-林道病、多发性内分泌肿瘤 (MEN) 综合征）、最终用户（医院、诊所、实验室、放射中心、诊断中心、其他）、分销渠道（直接招标、零售） |
|
覆盖国家 |
中国、日本、印度、韩国、新加坡、泰国、马来西亚、澳大利亚、菲律宾、印度尼西亚和亚太地区其他地区。 |
|
涵盖的市场参与者 |
Invitae Corporation、Illumina, Inc.、Natera, Inc.、CENTOGENE NV、4baseCare、Biocartis、Fulgent Genetics、Ambry Genetics、BioReference、PerkinElmer Inc.、LifeLabs、Abbott、BIO-HELIX、Cepheid、Eurofins Scientific 等。 |
亚太地区遗传性癌症检测市场定义
遗传性癌症是由遗传基因突变引起的任何癌症。某些基因的有害变异与癌症风险增加有关。基因检测可以估计一个人一生中患癌症的风险。这可以通过寻找基因、染色体或蛋白质的突变来实现。基因检测可用于多种类型的癌症。这些包括乳腺癌、卵巢癌、结肠癌、甲状腺癌、前列腺癌、胰腺癌、皮肤癌、肉瘤以及肾癌和胃癌。许多医学研究表明，5% 到 10% 的常见癌症被认为是遗传性的。进行基因测试以确定一个人是否携带有害的基因变异。这些测试还有助于确定尚未患癌症的家庭成员是否遗传了与已知具有癌症易感性替代方案的家庭成员相同的变异。
亚太地区遗传性癌症检测市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 遗传性癌症发病率上升
癌症是由细胞不受控制的生长引起的。癌症是由控制细胞生长和分裂的遗传信息（基因）发生有害变化（突变）引起的，这些变化会阻止细胞有效地发挥作用。
在遗传性癌症病例中，个体从父母一方遗传了突变的生长调节基因的副本，从另一方遗传了相同基因的工作副本。突变基因也称为“癌症易感基因”。由于这种癌症易感基因是遗传的，因此它存在于身体的每个细胞中，但该基因的工作副本使每个细胞正常运作。但是，如果突变破坏了细胞中基因的功能副本，细胞就会失去对其生长的控制并变成癌症。因此，继承癌症基因的个体在其一生中患上某些癌症的可能性要大得多。
因此，遗传性癌症发病率的上升增加了对遗传性癌症检测的需求，并可能成为亚太地区遗传性癌症检测市场增长的驱动力。
- 老年人口增加
癌症可能是老龄患者的疾病。在全球范围内，老年人口正在增加。老年人患遗传性癌症的风险更大。老年人口的增加可以为亚太地区遗传性癌症检测市场提供更好的服务。它预计亚太地区遗传性癌症检测市场的需求将激增。 人口老龄化正在导致人口结构的重新分配， 这将影响医疗保健的未来。毫无疑问，癌症的风险会随着年龄的增长而呈指数级增长。
根据全球最大的完整家族结构和医学证实的癌症数据库，遗传性癌症（包括其发病率和相关风险）在 8-20 岁人群中，父母或兄弟姐妹患病且无亲属的人群的发病率大约是正常人群的两倍。小肠癌、睾丸癌、甲状腺癌和骨癌的风险是正常人群的五到八倍。
因此，老年人口癌症发病率的增加预计将成为亚太地区遗传性癌症检测市场增长的一个驱动因素。
克制
- 遗传性癌症检测费用高昂
遗传性癌症检测采用技术高度先进的产品。这些产品的开发需要开发商进行严格的研究和开发。因此，程序和产品成本仍然很高，这相应地增加了检测成本。检测试剂盒价格昂贵，因为它们非常耗费资源，而且需要高薪医生、交通和昂贵的药物。
- 此外，检测程序也用于癌症检测。然而，此类程序非常昂贵，并且可能伴有并发症和更糟糕的长期结果。
因此，使用先进方式和技术产品进行癌症检测的高成本可能是亚太地区遗传性癌症检测市场增长的主要制约因素。
机会
-
市场参与者的战略举措
亚太地区遗传性癌症检测市场的崛起增加了对战略性商业理念的需求。它包括合作伙伴关系、业务扩展和其他发展。遗传性癌症治疗需求的激增显著增加了对诊断检测方法的需求。计划中的战略使市场参与者能够与组织的职能活动保持一致，以实现既定目标。它指导公司的讨论和决策，以确定实现目标所需的资源和预算，从而提高运营效率。
这些战略举措，例如主要市场参与者的产品发布、协议和业务扩展，将促进市场增长，并有望成为亚太地区遗传性癌症检测市场的机会。这些战略举措有望促进增长并改善公司的产品组合，最终带来更多收入。因此，市场参与者的这些战略举措有望成为亚太地区遗传性癌症检测市场增长的机会。
挑战
- 遗传性癌症检测面临的伦理挑战
在遗传性癌症基因检测过程中，一个重大的道德障碍是医疗专业人员缺乏有关基因检测的基本知识，并且对解释家族疾病模式缺乏信心。医疗服务提供者面临的挑战是提供足够的信息来支持患者的决策，并提供证据来支持他们可能提出的任何建议背后的理由。
缺乏报销会给医疗带来经济障碍。遗传性癌症风险评估和咨询的过程非常耗时，而且目前还不清楚如何最好地记录和计费这项服务。肿瘤学家经常被迫应对基因检测的潜在不确定的报销环境，第三方付款人的报销政策各不相同。
遗传性癌症基因检测引发了道德问题，而这些问题无法由患者或其家人解决。伦理、文化和宗教等各方面的问题不应成为遗传性癌症检测的障碍。所有这些都是需要解决的问题。因此，遗传性癌症检测过程中的道德挑战预计将对市场增长构成挑战。
新冠肺炎疫情对亚太地区遗传性癌症检测市场的影响
过去 18 个月，全球许多行业都处于不利地位。这可能是由于全球各地的工厂采取了各种预防措施，例如停工和其他限制，导致其工业和供应链流程遭受重大中断。亚太地区遗传性癌症检测市场也是如此。此外，由于大多数人的整体财务状况受到繁荣的严重影响，人们现在有更多机会从预算中排除非必要开支，因此消费需求随之下降。预计上述因素将在预测期内加重亚太地区遗传性癌症检测市场的收入利润。
制造商正在制定各种战略决策，以在新冠疫情后实现复苏。参与者正在进行多项研发活动、产品发布和战略合作，以改进移植诊断市场所涉及的技术和测试结果。
最新动态
- 2022 年 7 月，Helio Genomics 及其业务合作伙伴 Fulgent Genetics (FLGT) 宣布，美国医学会 (AMA) 为 HelioLiver 发布了新的 I 类现行程序术语 (CPT) 专有实验室分析代码，并在美国更广泛地采用先进的创新肝癌监测测试，这有助于该公司扩大其产品组合。
- 2022 年 3 月，Illumina, Inc. 推出了 n 体外诊断 (IVD) 试剂盒，一种癌症 RNA 测序仪。此次发布扩大了测序产品线，随后获得了上市后批准。它被描绘成线性市场增长。
亚太地区遗传性癌症检测市场范围
亚太地区遗传性癌症检测市场细分为检测类型、诊断类型、技术、疾病类型、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
按测试类型
- 多面板测试
- 单点基因测试
根据测试类型，亚太地区遗传性癌症检测市场分为多组测试和单点基因测试。
按诊断类型
- 活检
- 成像
- 实验室测试
根据诊断类型，亚太地区遗传性癌症检测市场分为活检、影像和实验室测试。
按技术分类
- 测序
- 聚合酶链式反应（PCR）
- 微阵列
根据技术，亚太地区遗传性癌症检测市场分为测序、聚合酶链反应（PCR）和微阵列。
按疾病类型
- 遗传性乳腺癌和卵巢癌综合征
- 考登综合症
- 林奇综合症
- 遗传性白血病和血液系统恶性肿瘤综合征
- 家族性腺瘤性息肉病 (FAP)
- 李法美尼症候群
- 希佩尔-林道病
- 多发性内分泌肿瘤（男性）综合征
根据疾病类型，亚太地区遗传性癌症检测市场细分为遗传性乳腺癌和卵巢癌综合征、考登综合征、林奇综合征、遗传性白血病和血液系统恶性肿瘤综合征、家族性腺瘤性息肉病 (FAP)、李-法美尼综合征、沃尔-希佩尔-林道病、多发性内分泌肿瘤 (MEN) 综合征。
由最终用户
根据最终用户，亚太遗传性癌症检测市场分为医院、诊所、实验室、放射中心、诊断中心和其他。
按分销渠道
- 直接招标
- 零售销售
根据分销渠道，亚太地区遗传癌症检测市场分为直接招标、零售。
亚太地区遗传性癌症检测市场区域分析/见解
对亚太地区遗传性癌症检测市场进行分析，并按检测类型、诊断类型、技术、疾病类型、最终用户和分销渠道提供市场规模信息。
本市场报告涵盖的国家包括中国、日本、印度、韩国、新加坡、泰国、马来西亚、澳大利亚、菲律宾、印度尼西亚和亚太地区其他国家。
- 2022 年，中国将凭借其在癌症诊断领域的最新先进技术和发明占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了亚太品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战，以及销售渠道的影响。
竞争格局和亚太地区遗传性癌症检测市场份额分析
亚太地区遗传性癌症检测市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对亚太地区遗传性癌症检测市场的关注有关。
亚太地区遗传性癌症检测市场的一些主要参与者包括 Invitae Corporation、Illumina, Inc.、Natera, Inc.、CENTOGENE NV、4baseCare、Biocartis、Fulgent Genetics、Ambry Genetics、BioReference、PerkinElmer Inc.、LifeLabs、Abbott、BIO-HELIX、Cepheid、Eurofins Scientific 等。
研究方法：亚太地区遗传性癌症检测市场
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、亚太地区与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC HEREDITARY CANCER TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCE OF HEREDITARY CANCER
6.1.2 INCREASE IN THE GERIATRIC POPULATION
6.1.3 RISING HEALTHCARE SPENDING
6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING
6.2 RESTRAINTS
6.2.1 HIGH COST OF HEREDITARY CANCER TESTING
6.2.2 LACK OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS
6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES
6.4 CHALLENGES
6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING
6.4.2 RISING COMPETITION AMONG MARKET PLAYERS
7 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY TEST TYPE
7.1 OVERVIEW
7.2 MULTI PANEL TEST
7.3 SINGLE-SITE GENETIC TEST
8 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE
8.1 OVERVIEW
8.2 BIOPSY
8.2.1 NEEDLE BIOPSIES
8.2.2 ENDOSCOPIC BIOPSIES
8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY
8.2.4 LAPAROTOMY AND THORACOTOMY
8.2.5 OTHERS
8.3 IMAGING
8.3.1 MAGNETIC RESONANCE IMAGING (MRI)
8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
8.3.4 NUCLEAR SCAN
8.3.5 ULTRASOUND
8.3.6 X-RAYS
8.4 LAB TESTS
8.4.1 BLOOD
8.4.2 URINE
8.4.3 OTHERS
9 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 POLYMERASE CHAIN REACTION (PCR)
9.3 SEQUENCING
9.4 MICRO ARRAY
10 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME
10.3 COWDEN SYNDROME
10.4 LYNCH SYNDROME
10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME
10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
10.7 LI-FRAUMENI SYNDROME
10.8 VON HIPPEL-LINDAU DISEASE
10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME
11 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 DIAGNOSTIC CENTERS
11.5 RADIOLOGY CENTERS
11.6 LABORATORIES
11.7 OTHERS
12 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY REGION
13.1 ASIA-PACIFIC
13.1.1 CHINA
13.1.2 JAPAN
13.1.3 SOUTH KOREA
13.1.4 INDIA
13.1.5 AUSTRALIA
13.1.6 SINGAPORE
13.1.7 THAILAND
13.1.8 MALAYSIA
13.1.9 INDONESIA
13.1.10 PHILIPPINES
13.1.11 REST OF ASIA-PACIFIC
14 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBOTT
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 ILLUMINA, INC. (2021)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 PERKINELMER INC. (2021)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 LIFELABS GENETICS
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 EUROFINS SCIENTIFIC (2021)
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 AMBRY GENETICS
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 BIOCARTIS
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 BIO-HELIX
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021)
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 CENTOGENE N.V. (2021)
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CEPHEID
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 FULGENT GENETICS
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 INVITAE CORPORATION
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 NATERA, INC. (2021)
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 4BASECARE.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 2 ASIA PACIFIC MULTI PANEL TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC SINGLE-SITE GENETIC TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC IMAGING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC IMAGING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC POLYMERASE CHAIN REACTION (PCR) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC SEQUENCING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC MICROARRAY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC HEREDITARY BREAST & OVARIAN CANCER SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC COWDEN SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC LYNCH SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS (FAP) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC LI-FRAUMENI SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC VON HIPPEL-LINDAU DISEASE IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC HOSPITALS CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC CLINICS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC DIAGNOSTIC CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC RADIOLOGY CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC LABORATORIES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC OTHERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC DIRECT TENDER IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC RETAIL SALES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 35 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 36 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 37 ASIA-PACIFIC BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 44 CHINA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 45 CHINA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 46 CHINA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 47 CHINA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 48 CHINA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 49 CHINA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 50 CHINA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 51 CHINA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 52 CHINA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 53 CHINA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 54 CHINA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 JAPAN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 56 JAPAN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 57 JAPAN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 58 JAPAN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 59 JAPAN BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 60 JAPAN IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 61 JAPAN LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 62 JAPAN HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 63 JAPAN HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 64 JAPAN HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 65 JAPAN HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 67 SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 68 SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 69 SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 70 SOUTH KOREA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 71 SOUTH KOREA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 72 SOUTH KOREA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 73 SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 74 SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 75 SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 76 SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 77 INDIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 78 INDIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 79 INDIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 80 INDIA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 81 INDIA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 82 INDIA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 83 INDIA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 84 INDIA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 85 INDIA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 86 INDIA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 87 INDIA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 88 AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 89 AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 90 AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 91 AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 92 AUSTRALIA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 93 AUSTRALIA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 94 AUSTRALIA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 95 AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 96 AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 97 AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 98 AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 99 SINGAPORE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 100 SINGAPORE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 101 SINGAPORE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 102 SINGAPORE HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 103 SINGAPORE BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 104 SINGAPORE IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 105 SINGAPORE LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 106 SINGAPORE HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 107 SINGAPORE HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 108 SINGAPORE HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 109 SINGAPORE HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 THAILAND HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 111 THAILAND HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 112 THAILAND HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 113 THAILAND HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 114 THAILAND BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 115 THAILAND IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 116 THAILAND LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 117 THAILAND HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 118 THAILAND HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 119 THAILAND HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 120 THAILAND HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 121 MALAYSIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 122 MALAYSIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 123 MALAYSIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 124 MALAYSIA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 125 MALAYSIA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 126 MALAYSIA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 127 MALAYSIA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 128 MALAYSIA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 129 MALAYSIA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 130 MALAYSIA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 131 MALAYSIA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 132 INDONESIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 133 INDONESIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 134 INDONESIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 135 INDONESIA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 136 INDONESIA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 137 INDONESIA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 138 INDONESIA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 139 INDONESIA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 140 INDONESIA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 141 INDONESIA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 142 INDONESIA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 143 PHILIPPINES HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 144 PHILIPPINES HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 145 PHILIPPINES HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 146 PHILIPPINES HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 147 PHILIPPINES BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 148 PHILIPPINES IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 149 PHILIPPINES LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 150 PHILIPPINES HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 151 PHILIPPINES HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 152 PHILIPPINES HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 153 PHILIPPINES HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 154 REST OF ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: SEGMENTATION
FIGURE 11 EXPANDING REPRODUCTIVE GENETIC HEALTH SPACE IS EXPECTED TO DRIVE THE ASIA PACIFIC HEREDITARY CANCER TESTING MARKET IN THE FORECAST PERIOD
FIGURE 12 MULTI PANEL TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC HEREDITARY CANCER TESTING MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC HEREDITARY CANCER TESTING MARKET
FIGURE 14 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2021
FIGURE 15 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2022-2029 (USD MILLION)
FIGURE 16 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, CAGR (2022-2029)
FIGURE 17 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2021
FIGURE 19 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2022-2029 (USD MILLION)
FIGURE 20 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, CAGR (2022-2029)
FIGURE 21 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2021
FIGURE 23 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2020-2029 (USD MILLION)
FIGURE 24 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 25 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2021
FIGURE 27 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 28 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 29 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 30 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY END USER, 2021
FIGURE 31 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY END USER, 2020-2029 (USD MILLION)
FIGURE 32 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY END USER, CAGR (2022-2029)
FIGURE 33 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY END USER, LIFELINE CURVE
FIGURE 34 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2021
FIGURE 35 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 36 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 37 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET: SNAPSHOT (2021)
FIGURE 39 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021)
FIGURE 40 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET: BY TEST TYPE (2022-2029)
FIGURE 43 ASIA PACIFIC HEREDITARY CANCER TESTING MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
